Samsung Bioepis secures 10-year exclusive drug supply deal in Brazil
Samsung Bioepis has secured a decade-long exclusive supply deal for a rare disease treatment in Brazil, strengthening its position in Latin America’s largest pharmaceutical market while opening a new chapter in its partnership with the Brazilian government. The Korean biopharmaceutical company said Tuesday it had signed a local partnership agreement to supply SB12, a biosimilar of Soliris with…
Samsung Bioepis has secured a 10-year exclusive supply deal for SB12, a biosimilar of Soliris, in Brazil, marking a significant milestone for the Korean biopharmaceutical company in the Latin American market. The partnership agreement with the Brazilian Ministry of Health will provide a stable source of revenue for Samsung Bioepis, with the drug SB12 used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
The agreement was facilitated through the government-led Productive Development Partnership program, further solidifying Samsung Bioepis' commitment to the Brazilian pharmaceutical market.
Brief written by urgent.news from The Korea Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- Samsung Bioepis secures 10-year exclusive drug supply deal in Brazil koreatimes.co.kr
